César Caraballo

César Caraballo

Auto-generated profile, based on publicly available information

César Caraballo

Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
CCCésar Caraballo
César Caraballo
NDNihar R. Desai
Nihar R. Desai
HMHillary Mulder
Hillary Mulder
BABrooke Alhanti
Brooke Alhanti
FWF. Perry Wilson
F. Perry Wilson
TATariq Ahmad
Tariq Ahmad
Background: The New York Heart Association ( NYHA ) classification has served as a fundamental tool for risk stratification of heart failure ( HF ) and determines clinical trial eligibility and candidacy for drugs and devices. However, its ability to adequately stratify risk is unclear. Methods and Results: To compare NYHA class with objective assessments and survival in patients with HF , we performed secondary analyses of 4 multicenter National Institutes of Health–funded HF clinical trials that included patients classified as NYHA class II or III: TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), DIG (The Effect of Digoxin on Mortality and Morbidity in Patients With Heart Failure), HF‐ACTION (Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure), and GUIDE‐IT (Guiding Evidence‐Based Therapy Using Biomarker Intensified Treatment in Heart Failure). Twenty‐month cumulative survival was compared between classes using Kaplan–Meier curves and the log rank test. NT ‐proBNP (N‐terminal pro–B‐type natriuretic peptide), Kansas City Cardiomyopathy Questionnaire ( KCCQ ) scores, 6‐minute walk distances, left ventricular ejection fraction, and cardiopulmonary test parameters were compared using Wilcoxon rank sum tests and percentage overlap using kernel density estimations. Cumulative mortality varied significantly across NYHA classes and HF clinical trials (likelihood ratio, P <0.001). Mortality at 20 months for NYHA class II ranged from 7% for patients in HF ‐ ACTION to 15% in GUIDE ‐ IT , whereas mortality for NYHA class III ranged from 12% in TOPCAT to 26% in GUIDE ‐ IT . There was substantial percentage overlap in values for NT ‐pro BNP levels (79% and 69%), KCCQ scores (63% and 54%), 6‐minute walk distances (63% and 54%), and left ventricular ejection fraction (88% and 83%). Similarly, there was substantial overall in values for minute ventilation–carbon dioxide production relationship (71%), maximal oxygen uptake (54%), and exercise duration (53%). Conclusions: The NYHA system poorly discriminates HF patients across the spectrum of functional impairment. These findings raise important questions about the need for improved phenotyping of these patients to facilitate risk stratification and response to interventions.


1 February 2020 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
CCCésar Caraballo
César Caraballo
JVJavier Valero-Elizondo
Javier Valero-Elizondo
RKRohan Khera
Rohan Khera
SMShiwani Mahajan
Shiwani Mahajan
GGGowtham R. Grandhi
Gowtham R. Grandhi
KNKhurram Nasir
Khurram Nasir
Background: The trend of increasing total and out-of-pocket expenditure among patients with diabetes mellitus represents a risk of financial hardship for Americans and a threat to medical and nonmedical needs. We aimed to describe the national scope and associated tradeoffs of financial hardship from medical bills among nonelderly individuals with diabetes mellitus. Methods and Results: We used the National Health Interview Survey data from 2013 to 2017, including adults ≤64 years old with a self-reported diagnosis of diabetes mellitus. Among 164 696 surveyed individuals, 8967 adults ≤64 years old reported having diabetes mellitus, representing 13.1 million individuals annually across the United States. The mean age was 51.6 years (SD 10.3), and 49.1% were female. A total of 41.1% were part of families that reported having financial hardship from medical bills, with 15.6% reporting an inability to pay medical bills at all. In multivariate analyses, individuals who lacked insurance, were non-Hispanic black, had low income, or had high-comorbidity burden were at higher odds of being in families with financial hardship from medical bills. When comparing the graded categories of financial hardship, there was a stepwise increase in the prevalence of high financial distress, food insecurity, cost-related nonadherence, and foregone/delayed medical care, reaching 70.5%, 49.4%, 49.5%, and 74% among those unable to pay bills, respectively. Compared with those without diabetes mellitus, individuals with diabetes mellitus had higher odds of financial hardship from medical bills (adjusted odds ratio [aOR], 1.27 [95% CI, 1.18–1.36]) or any of its consequences, including high financial distress (aOR, 1.14 [95% CI, 1.05–1.24]), food insecurity (aOR, 1.27 [95% CI, 1.16–1.40]), cost-related medication nonadherence (aOR, 1.43 [95% CI, 1.30–1.57]), and foregone/delayed medical care (aOR, 1.30 [95% CI, 1.20–1.40]). Conclusions: Nonelderly patients with diabetes mellitus have a high prevalence of financial hardship from medical bills, with deleterious consequences.

1 October 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
CHChenxi Huang
Chenxi Huang
SLShu-Xia Li
Shu-Xia Li
CCCésar Caraballo
César Caraballo
FMFrederick A. Masoudi
Frederick A. Masoudi
JRJohn S. Rumsfeld
John S. Rumsfeld
HKHarlan M. Krumholz
Harlan M. Krumholz
Background: New methods such as machine learning techniques have been increasingly used to enhance the performance of risk predictions for clinical decision-making. However, commonly reported performance metrics may not be sufficient to capture the advantages of these newly proposed models for their adoption by health care professionals to improve care. Machine learning models often improve risk estimation for certain subpopulations that may be missed by these metrics. Methods and Results: This article addresses the limitations of commonly reported metrics for performance comparison and proposes additional metrics. Our discussions cover metrics related to overall performance, discrimination, calibration, resolution, reclassification, and model implementation. Models for predicting acute kidney injury after percutaneous coronary intervention are used to illustrate the use of these metrics. Conclusions: We demonstrate that commonly reported metrics may not have sufficient sensitivity to identify improvement of machine learning models and propose the use of a comprehensive list of performance metrics for reporting and comparing clinical risk prediction models.

1 February 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
MMMegan McCullough
Megan McCullough
CCCesar Caraballo
Cesar Caraballo
NRNeal G. Ravindra
Neal G. Ravindra
PMP. Elliott Miller
P. Elliott Miller
CMCatherine Mezzacappa
Catherine Mezzacappa
NDNihar R. Desai
Nihar R. Desai
Patients with stage D heart failure (HF) have limited life-prolonging therapeutic options other than left ventricular assist devices (LVADs) and cardiac transplant.1 As few patients can undergo transplant and outcomes with mechanical circulatory support have greatly improved, the population of patients with durable LVADs is increasing.2 However, data on the use of pharmacotherapy beyond the use of anticoagulation to prevent thrombotic events are limited. Specifically, little is known about the association of neurohormonal blockade (NHB) with clinical outcomes in patients with LVADs.

7 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
FCFouad Chouairi
Fouad Chouairi
MFMichael Fuery
Michael Fuery
KCKatherine A. Clark
Katherine A. Clark
CMClancy W. Mullan
Clancy W. Mullan
JSJames Stewart
James Stewart
EMElliott Miller
Elliott Miller
Background: Racial and ethnic disparities contribute to differences in access and outcomes for patients undergoing heart transplantation. We evaluated contemporary outcomes for heart transplantation stratified by race and ethnicity as well as the new 2018 allocation system. Methods and Results: Adult heart recipients from 2011 to 2020 were identified in the United Network for Organ Sharing database and stratified into 3 groups: Black, Hispanic, and White. We analyzed recipient and donor characteristics, and outcomes. Among 32 353 patients (25% Black, 9% Hispanic, 66% White), Black and Hispanic patients were younger, more likely to be women and have diabetes mellitus or renal disease (all, P <0.05). Over the study period, the proportion of Black and Hispanic patients listed for transplant increased: 21.7% to 28.2% ( P =0.003) and 7.7% to 9.0% ( P =0.002), respectively. Compared with White patients, Black patients were less likely to undergo transplantation (adjusted hazard ratio [aHR], 0.87; CI, 0.84–0.90; P <0.001), but had a higher risk of post‐transplant death (aHR, 1.14; CI, 1.04–1.24; P =0.004). There were no differences in transplantation likelihood or post‐transplant mortality between Hispanic and White patients. Following the allocation system change, transplantation rates increased for all groups ( P <0.05). However, Black patients still had a lower likelihood of transplantation than White patients (aHR, 0.90; CI, 0.79–0.99; P =0.024). Conclusions: Although the proportion of Black and Hispanic patients listed for cardiac transplantation have increased, significant disparities remain. Compared with White patients, Black patients were less likely to be transplanted, even with the new allocation system, and had a higher risk of post‐transplantation death.